794 related articles for article (PubMed ID: 22182934)
21. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
22. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.
Lichtman AH; Martin BR
Pharmacol Biochem Behav; 1997; 57(1-2):7-12. PubMed ID: 9164547
[TBL] [Abstract][Full Text] [Related]
23. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
24. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine.
Williams CM; Kirkham TC
Pharmacol Biochem Behav; 2002; 71(1-2):333-40. PubMed ID: 11812541
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects.
Rahn EJ; Thakur GA; Wood JA; Zvonok AM; Makriyannis A; Hohmann AG
Pharmacol Biochem Behav; 2011 Jun; 98(4):493-502. PubMed ID: 21382397
[TBL] [Abstract][Full Text] [Related]
26. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat.
Cox ML; Welch SP
Eur J Pharmacol; 2004 Jun; 493(1-3):65-74. PubMed ID: 15189765
[TBL] [Abstract][Full Text] [Related]
27. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
28. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
Järbe TU; Lamb RJ; Liu Q; Makriyannis A
Eur J Pharmacol; 2003 Apr; 466(1-2):121-7. PubMed ID: 12679148
[TBL] [Abstract][Full Text] [Related]
29. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.
Kinsey SG; Wise LE; Ramesh D; Abdullah R; Selley DE; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2013 Jun; 345(3):492-501. PubMed ID: 23412396
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor.
Raborn ES; Cabral GA
J Pharmacol Exp Ther; 2010 Apr; 333(1):319-27. PubMed ID: 20089805
[TBL] [Abstract][Full Text] [Related]
31. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
32. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain.
Benamar K; Geller EB; Adler MW
J Pharmacol Exp Ther; 2008 May; 325(2):641-5. PubMed ID: 18281594
[TBL] [Abstract][Full Text] [Related]
33. Cannabimimetic properties of ajulemic acid.
Vann RE; Cook CD; Martin BR; Wiley JL
J Pharmacol Exp Ther; 2007 Feb; 320(2):678-86. PubMed ID: 17105826
[TBL] [Abstract][Full Text] [Related]
34. Sex differences in anti-allodynic, anti-hyperalgesic and anti-edema effects of Δ(9)-tetrahydrocannabinol in the rat.
Craft RM; Kandasamy R; Davis SM
Pain; 2013 Sep; 154(9):1709-1717. PubMed ID: 23707295
[TBL] [Abstract][Full Text] [Related]
35. The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors.
da Fonseca Pacheco D; Klein A; de Castro Perez A; da Fonseca Pacheco CM; de Francischi JN; Duarte ID
Br J Pharmacol; 2008 Jul; 154(5):1143-9. PubMed ID: 18469844
[TBL] [Abstract][Full Text] [Related]
36. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.
Liu Q; Bhat M; Bowen WD; Cheng J
J Pharmacol Exp Ther; 2009 Dec; 331(3):1062-70. PubMed ID: 19752241
[TBL] [Abstract][Full Text] [Related]
37. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells.
Gkoumassi E; Dekkers BG; Dröge MJ; Elzinga CR; Schmidt M; Meurs H; Zaagsma J; Nelemans SA
Br J Pharmacol; 2007 Aug; 151(7):1041-8. PubMed ID: 17558435
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
39. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
Stewart JL; McMahon LR
J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
[TBL] [Abstract][Full Text] [Related]
40. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
Darmani NA
Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
